{"title":"FDA批准普拉塞替尼用于治疗成人转移性RET融合阳性NSCLC。","authors":"Kevin M Wright","doi":"10.46883/ONC.2020.3410.0406","DOIUrl":null,"url":null,"abstract":"<p><p>The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"406-406;431"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.\",\"authors\":\"Kevin M Wright\",\"doi\":\"10.46883/ONC.2020.3410.0406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.</p>\",\"PeriodicalId\":520728,\"journal\":{\"name\":\"Oncology (Williston Park, N.Y.)\",\"volume\":\" \",\"pages\":\"406-406;431\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology (Williston Park, N.Y.)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.46883/ONC.2020.3410.0406\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology (Williston Park, N.Y.)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/ONC.2020.3410.0406","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.
The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
